Biomarker Core
Biomarker Core
批准号:
10666448
负责人:
LEE-WAY JIN
金额:
$32.37万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-15 至 2026-06-30
关键词:
Alzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAmyloidAmyloid beta-ProteinBar CodesBiologicalBiological MarkersBloodBlood specimenBrain InjuriesCategoriesClinicalClinical TrialsCognitiveCognitive agingCollaborationsCollectionCommunitiesComplexComputer softwareDNADataDatabasesDementiaDepositionDiagnosticDiseaseElderlyEpidemiologyEquipment and supply inventoriesFacultyFreezingFundingGeneticGoalsGrantHeterogeneityImpaired cognitionIndividualInfrastructureInterventionLifeLongitudinal cohortMentorsOutcomePathologic ProcessesPathologyPhenotypePlasmaPopulation HeterogeneityProceduresProcessQualifyingRNARaceRegulationResearchResearch PersonnelResourcesRetrievalSamplingSecureSerumSpecimenStandardizationStudy SubjectSystemTechnologyTimeValidationWorkaccurate diagnosisbiobankbiomarker discoveryblood-based biomarkercareer developmentclinical epidemiologycohortcost efficientdata sharingepidemiology studyfrontierglycoproteomicsindexinginnovationlipidomicsmetabolomicsmulti-ethnicmultiple omicsneuroimagingneuropathologynovel markeroperationprogramsprotein biomarkersrepositoryresearch and developmentresponserisk prediction modelsaliva samplesample collectionspecific biomarkersstandardize measuretau Proteinstau-1toolweb based interfaceweb portal
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY – Biomarker Core
The overarching goal of the UCD ADRC is to understand the multiple and complex determinants that explain
heterogeneity of cognitive trajectories and progression to dementia among a cohort of diverse older adults. In
line with this goal, our study subjects form a diverse multi-ethnic/racial longitudinal cohort. To be able to offer
disease-modifying interventions in the subject’s lifetime, a precise and dynamic biological definition of the
subject’s disease trajectory is essential. It requires a comprehensive biomarker assessment of both AD
pathology and non-AD specific brain injury that may contribute to and modify the trajectories of cognitive
decline. This task is particularly critical when faced with mixed pathological processes manifested by subjects
of diverse backgrounds. To meet this challenge, the UC Davis ADRC launched a biorepository in 2014 to
collect blood specimens and establish standard operation procedures. We have since grown substantially in
expertise and sample collection via continuous funding through several NIA- and Alzheimer’s Association-
funded blood biomarker, clinical trial, and epidemiological projects, as well as participation in national programs
such as MarkVCID, ADNI, NCRAD, and AD Metabolomic Consortium. Currently we have deposited thousands
of blood specimens (serum, plasma, DNA, and RNA) from 1279 subjects in our ADRC Longitudinal Cohort;
hundreds of them have given longitudinal samples. We have also collected saliva and blood samples from
hundreds of subjects participating in ADRC-affiliated clinical trials and epidemiological projects such as the Life
After 90 Study. Sample categorization, inventory, tracking, and retrieval are conducted by the barcode-based
OpenSpecimen network software, which is further integrated into the ADRC Web-based interface. Moreover,
we have established expertise in ultra-sensitive protein biomarker analysis using SiMoA technology, and built a
broad multi-omics platform for collaboration by providing expertise and resources for emerging omics
technology including glycomics, glycoproteomics, lipidomics, and metabolomics. In this ADRC application, we
will formally establish the Biomarker Core (BC), which will accomplish the following four specific aims: Aim 1 –
to expand the repository of high-quality samples from diverse populations; Aim 2 – to quantify and integrate
essential and emerging blood biomarkers to support diagnostics and theragnostics efforts of ADRC; Aim 3 – to
provide infrastructure to support novel biomarker discovery, clinical trials, and UCD ADRC-affiliated clinical and
epidemiological projects; and Aim 4 – to extend our existing robust and cost-efficient systems for sharing data
and specimens broadly with the research community to support innovative research and career development.
We believe the deposited data and specimens from our diverse multi-ethnic/racial longitudinal cohort will
constitute a unique, readily sharable resource to enable cognitive stage-dependent analyses of inter-related
biomarkers in data- and hypothesis-driven studies. Our expertise in SiMoA, glycomics, lipidomics, and
metabolomics will help investigators nationwide to advance into new frontiers of biomarker discovery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarker Core
-
批准号:10461126
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2021
-
负责人:LEE-WAY JIN
-
依托单位:
Biomarker Core
-
批准号:10264666
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2021
-
负责人:LEE-WAY JIN
-
依托单位:
Neuropathology Core
-
批准号:10264664
-
项目类别:
-
资助金额:$32.71万
-
财政年份:2021
-
负责人:LEE-WAY JIN
-
依托单位:
Neuropathology Core
-
批准号:10666440
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2021
-
负责人:LEE-WAY JIN
-
依托单位:
Neuropathology Core
-
批准号:10461124
-
项目类别:
-
资助金额:$33.24万
-
财政年份:2021
-
负责人:LEE-WAY JIN
-
依托单位:
Repository Core
-
批准号:10266152
-
项目类别:
-
资助金额:$259.71万
-
财政年份:2020
-
负责人:LEE-WAY JIN
-
依托单位:
Repository Core
-
批准号:10489297
-
项目类别:
-
资助金额:$391.23万
-
财政年份:2020
-
负责人:LEE-WAY JIN
-
依托单位:
The potassium channel Kv1.3 in perinatal brain injury
-
批准号:10084329
-
项目类别:
-
资助金额:$42.7万
-
财政年份:2019
-
负责人:LEE-WAY JIN
-
依托单位:
The potassium channel Kv1.3 in perinatal brain injury
-
批准号:9893936
-
项目类别:
-
资助金额:$43.24万
-
财政年份:2019
-
负责人:LEE-WAY JIN
-
依托单位:
The potassium channel Kv1.3 in perinatal brain injury
-
批准号:10329972
-
项目类别:
-
资助金额:$42.13万
-
财政年份:2019
-
负责人:LEE-WAY JIN
-
依托单位:
The potassium channel Kv1.3 in perinatal brain injury
-
批准号:10551853
-
项目类别:
-
资助金额:$40.71万
-
财政年份:2019
-
负责人:LEE-WAY JIN
-
依托单位:
Comprehensive Characterization of Glycosylation Alterations in Alzheimer's Disease
-
批准号:10445264
-
项目类别:
-
资助金额:$65.62万
-
财政年份:2018
-
负责人:LEE-WAY JIN
-
依托单位:
Comprehensive Characterization of Glycosylation Alterations in Alzheimer's Disease
-
批准号:9974465
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2018
-
负责人:LEE-WAY JIN
-
依托单位:
Comprehensive Characterization of Glycosylation Alterations in Alzheimer’s Disease
-
批准号:9789176
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2018
-
负责人:LEE-WAY JIN
-
依托单位:
Comprehensive Characterization of Glycosylation Alterations in Alzheimer's Disease
-
批准号:10210355
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2018
-
负责人:LEE-WAY JIN
-
依托单位:
Mitochondrial ROS and Microglia in Rett Syndrome
-
批准号:10216313
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2017
-
负责人:LEE-WAY JIN
-
依托单位:
Mitochondrial ROS and Microglia in Rett Syndrome
-
批准号:9975010
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2017
-
负责人:LEE-WAY JIN
-
依托单位:
Mitochondrial ROS and Microglia in Rett Syndrome
-
批准号:9311039
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2017
-
负责人:LEE-WAY JIN
-
依托单位:
The Microglial Kv1.3 Channel in Alzheimer's Disease
-
批准号:8307777
-
项目类别:
-
资助金额:$15.61万
-
财政年份:2011
-
负责人:LEE-WAY JIN
-
依托单位:
The role of astrocytes in Rett syndrome
-
批准号:8206482
-
项目类别:
-
资助金额:$32.67万
-
财政年份:2011
-
负责人:LEE-WAY JIN
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: